Benzene, chloro-
RTECS #
CZ0175000
CAS #
Updated
June 2018
Molecular Weight
112.56
Molecular Formula
C6H5Cl
Synonyms
Benzene chloride
Chloorbenzeen (Dutch)
Chlorbenzene
Chlorbenzol
Chlorobenzen (Polish)
Chlorobenzene
Chlorobenzene (ACGIH:OSHA)
Chlorobenzenu (Czech)
Clorobenzene (Italian)
MCB
Monochloorbenzeen (Dutch)
Monochlorbenzene
Monochlorbenzol (German)
Monochlorobenzene
Monochlorobenzene (OSHA)
Monoclorobenzene (Italian)
NCI-C54886
Phenyl chloride
Tetrosin SP
Chloorbenzeen (Dutch)
Chlorbenzene
Chlorbenzol
Chlorobenzen (Polish)
Chlorobenzene
Chlorobenzene (ACGIH:OSHA)
Chlorobenzenu (Czech)
Clorobenzene (Italian)
MCB
Monochloorbenzeen (Dutch)
Monochlorbenzene
Monochlorbenzol (German)
Monochlorobenzene
Monochlorobenzene (OSHA)
Monoclorobenzene (Italian)
NCI-C54886
Phenyl chloride
Tetrosin SP
Mutation Data and Reference
| System Test | Route/Organism/Tissue | Dose | Reference |
|---|---|---|---|
| Cytogenetic Analysis | intraperitoneal/mouse | 1 gm/kg | EMMUEG 25,302,1995 |
| Cytogenetic Analysis | inhalation/rat | 500 µg/L/275D- intermittent | VCVGK* -,20,1994 |
| gene conversion and mitotic recombination | /Saccharomyes cerevisiae | 1000 ppm | NTIS** PB84-138973 |
| micronucleus test | intraperitoneal/mouse | 225 mg/kg/24H | MUTAEX 2,111,1987 |
| micronucleus test | intraperitoneal/mouse | 225 mg/kg | HPV173 -,-,2002 |
| mutation in mammalian somatic cells | lymphocyte/mouse | 100 mg/L | EMMUEG 12,85,1988 |
| mutation in microorganisms | lymphocyte/mouse | 70 mg/L (+enzymatic activation step) | EMMUEG 12,85,1988 |
| sister chromatid exchange | ovary/hamster | 300 mg/L | SCIEAS 236,933,1987 |
| specific locus test | other cell types/mouse | 67.56 mg/L/3H (+enzymatic activation step) | MUTAEX 25,539,2010 |
Reproductive Effects Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/rat | 75 ppm/6H (6-15D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system | TXAPA9 76,365,1984 |
| inhalation/rat | 210 ppm/6H (6-15D pregnant) | Reproductive: Specific developmental abnormalities: Hepatobiliary system | TXAPA9 76,365,1984 |
| inhalation/rabbit | 590 ppm/6H (6-18D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) | TXAPA9 76,365,1984 |
| inhalation/rabbit | 10 ppm/6H (6-18D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system | TXAPA9 76,365,1984 |
| inhalation/rat | 2760 mg/kg (6-15D pregnant) | Reproductive: Other effects on female Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system | HPV173 -,-,2002 |
| inhalation/rabbit | 210 ppm (6-18D pregnant) | Reproductive: Other effects on female | HPV173 -,-,2002 |
| inhalation/rat | 150 ppm (multigeneration) | Reproductive: Other effects on male Reproductive: Other effects on female | HPV173 -,-,2002 |
| inhalation/rat | 590 ppm (6-15D pregnant) | Reproductive: Other effects on female Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system | HPV173 -,-,2002 |
Tumorigenic Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| oral/rat | lowest published toxic dose: 61800 mg/kg/2Y- intermittent | Tumorigenic: Neoplastic by RTECS criteria Liver: Tumors Blood: Tumors | NTPTR* NTP-TR-261,1985 |
| oral/rat | lowest published toxic dose: 61800 mg/kg/103W- intermittent | Tumorigenic: Neoplastic by RTECS criteria Liver: Tumors | NTIS** PB86-144714/AS |
| oral/rat | lowest published toxic dose: 61800 mg/kg/103W- intermittent | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Liver: Tumors Tumorigenic: Increased incidence of tumors in susceptible strains | HPV173 -,-,2002 |
Acute Toxicity Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| In Vitro/Human, leukemia cells | Inhibitor Concentration (5 percent kill): 1970 mg/L/30M | In Vitro Toxicity Studies: Cell counting | TIVIEQ 27,857,2013 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration Low: 4000 mg/L/30M | In Vitro Toxicity Studies: Cell counting In Vitro Toxicity Studies: Other assays | TIVIEQ 27,857,2013 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration (25 percent kill): 597.2 mg/L/24H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 26,1150,2012 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (30 percent kill): >200 mg/L/45H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 29,901,2015 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (50 percent kill): >200 mg/L/45H | In Vitro Toxicity Studies: Other assays | TIVIEQ 29,901,2015 |
| In Vitro/Human, monocyte | Inhibitor Concentration Low: 552 mg/L/2H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,1233,2013 |
| In Vitro/Human, skin | Inhibitor Concentration (20 percent kill): 225.1 mg/L/21H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,314,2013 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 10 µmol/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TXAPA9 283,147,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): >2000 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): >2000 µmol/L/48H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (30 percent kill): >2000 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (30 percent kill): >2000 µmol/L/48H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 29,688,2015 |
| In Vitro/mra | Inhibitor Concentration (25 percent kill): 2031.6 mg/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 216,65,2013 |
| In Vitro/mra | Inhibitor Concentration Low: 20.316 mg/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TOLED5 216,65,2013 |
| In Vitro/Non-mammalian species, fibroblast | Inhibitor Concentration (50 percent kill): 6.77 mmol/L/24H | In Vitro Toxicity Studies: Cell counting | TIVIEQ 7,537,1993 |
| inhalation/mammal (species unspecified) | lethal concentration (50 percent kill): 10 gm/m3 | GTPZAB 32(10),25,1988 | |
| inhalation/mouse | Lowest published lethal concentration: 15 gm/m3 | GISAAA 20(8),19,1955 | |
| inhalation/mouse | lowest published toxic concentration: 700 ppm/6M | Lung, Thorax, or Respiration: Respiratory depression | TOLED5 9,137,1981 |
| inhalation/mouse | lethal concentration (50 percent kill): 4300 ppm/2H | ENTOX* -,556,2005 | |
| inhalation/mouse | lethal concentration (50 percent kill): 1886 ppm/6H | HPV173 -,-,2002 | |
| inhalation/rat | lethal concentration (50 percent kill): 2965 ppm/6H | HPV173 -,-,2002 | |
| inhalation/rat | lethal concentration (50 percent kill): 39700 mg/m3/3.75H | HPV173 -,-,2002 | |
| inhalation/rat | lethal concentration (50 percent kill): 2965 ppm | NTIS** OTS0521601 | |
| intraperitoneal/guinea pig | lowest published lethal dose: 4100 mg/kg | Behavioral: Muscle weakness Liver: Fatty liver degeneration Kidney, Ureter, and Bladder: Other changes | RMSRA6 16,449,1896 |
| intraperitoneal/mouse | lethal dose (50 percent kill): 515 mg/kg | PHMCAA 10,172,1968 | |
| intraperitoneal/rat | lethal dose (50 percent kill): 1655 mg/kg | FAATDF 5,105,1985 | |
| intraperitoneal/rat | lowest published toxic dose: 2 mg/kg | Liver: Other changes Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases | TXAPA9 111,69,1991 |
| intraperitoneal/rat | lowest published toxic dose: 1 mg/kg | Liver: Changes in liver weight | TXAPA9 111,69,1991 |
| oral/chicken | lowest published toxic dose: 800 mg/kg | Liver: Other changes Biochemical: Metabolism (intermediary): Porphyrin including bile pigments | VCVGK* -,19,1984 |
| oral/guinea pig | lethal dose (50 percent kill): 2250 mg/kg | 85GMAT -,34,1982 | |
| oral/mammal (species unspecified) | lethal dose (50 percent kill): 2300 mg/kg | GTPZAB 32(10),25,1988 | |
| oral/mouse | lethal dose (50 percent kill): 2300 mg/kg | ENTOX* -,556,2005 | |
| oral/rabbit | lethal dose (50 percent kill): 2250 mg/kg | 38MKAJ 2B,3603,1981 | |
| oral/rat | lethal dose (50 percent kill): 1110 mg/kg | Behavioral: Somnolence (general depressed activity) Behavioral: Tremor Behavioral: Ataxia | SRTCAC 36(1-4),10,1989 |
| oral/rat | lethal dose (50 percent kill): 1540 mg/kg | HPV173 -,-,2002 | |
| oral/rat | lethal dose (50 percent kill): 500 mg/kg | Behavioral: Ataxia Lung, Thorax, or Respiration: Respiratory depression | HPV173 -,-,2002 |
| skin/guinea pig | Lethal dose: >11 gm/kg | 85INA8 6,271,1991 | |
| skin/rabbit | Lethal dose: >2200 mg/kg | NTIS** AD-A180-198 | |
| skin/rabbit | lethal dose (50 percent kill): >7940 mg/kg | HPV173 -,-,2002 | |
| unreported route/mammal (species unspecified) | lethal dose (50 percent kill): 2300 mg/kg | GISAAA 51(5),61,1986 | |
| unreported route/rabbit | lethal dose (50 percent kill): 2830 mg/kg | Liver: Other changes | VCVGK* -,19,1984 |
| unreported route/rat | lowest published toxic dose: 0.026 mg/kg | Behavioral: Food intake (animal) Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other enzymes | VCVGK* -,19,1984 |
| unreported route/rat | lowest published lethal dose: 4000 mg/kg | Liver: Other changes | VCVGK* -,19,1984 |
| unreported route/rat | lethal dose (50 percent kill): 2950 mg/kg | Liver: Other changes | VCVGK* -,19,1984 |
Other Multiple Dose Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/Dog | lowest published toxic concentration: 1590 mg/m3/24W- intermittent | Gastrointestinal: Nausea or vomiting Liver: Changes in liver weight Endocrine: Changes in adrenal weight | HPV173 -,-,2002 |
| inhalation/rabbit | lowest published toxic concentration: 250 ppm/7H/24W- intermittent | Liver: Changes in liver weight Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases | NTIS** OTS0555046 |
| inhalation/rabbit | lowest published toxic concentration: 2.5 mg/m3/3W- intermittent | Liver: Fatty liver degeneration Blood: Changes in cell count (unspecified) Nutritional and Gross Metabolic: Weight loss or decreased weight gain | VCVGK* -,19,1994 |
| inhalation/rabbit | lowest published toxic concentration: 5 mg/m3/213D- intermittent | Endocrine: Adrenal cortex hyperplasia | VCVGK* -,20,1994 |
| inhalation/rat | lowest published toxic concentration: 1 mg/m3/60D- continuous | Brain and Coverings: Recordings from specific areas of CNS Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: True cholinesterase Biochemical: Metabolism (intermediary): Plasma proteins not involving coagulation | GISAAA 30(3),8,1965 |
| inhalation/rat | lowest published toxic concentration: 250 ppm/7H/24W- intermittent | Liver: Changes in liver weight Blood: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases | NTIS** OTS0555046 |
| oral/Dog | lowest published toxic dose: 17712 mg/kg/93D- intermittent | Blood: Changes in leukocyte (WBC) count Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | TXAPA9 19,393,1971 |
| oral/Dog | lowest published toxic dose: 3542.5 mg/kg/13W- intermittent | Behavioral: Food intake (animal) Nutritional and Gross Metabolic: Weight loss or decreased weight gain | HPV173 -,-,2002 |
| oral/Dog | lowest published toxic dose: 17712.5 mg/kg/13W- intermittent | Liver: Changes in liver weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | HPV173 -,-,2002 |
| oral/guinea pig | lowest published toxic dose: 441 mg/kg/63W- intermittent | Gastrointestinal: Gastritis Liver: Hepatitis (hepatocellular necrosis), zonal Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) | GISAAA 20(7),7,1955 |
| oral/mouse | lowest published toxic dose: 16250 mg/kg/13W- intermittent | Liver: Hepatitis (hepatocellular necrosis), diffuse Kidney, Ureter, and Bladder: Other changes in urine composition Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | JTEHD6 15,745,1985 |
| oral/mouse | lowest published toxic dose: 22750 mg/kg/13W- intermittent | Liver: Hepatitis (hepatocellular necrosis), diffuse Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | VCVGK* -,20,1994 |
| oral/mouse | lowest published toxic dose: 16250 mg/kg/13W- intermittent | Liver: Changes in liver weight Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | HPV173 -,-,2002 |
| oral/rabbit | lowest published toxic dose: 441 mg/kg/63W- intermittent | Gastrointestinal: Gastritis Liver: Hepatitis (hepatocellular necrosis), zonal Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) | GISAAA 20(7),7,1955 |
| oral/rat | lowest published toxic dose: 14 gm/kg/14D- intermittent | Behavioral: Somnolence (general depressed activity) Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | JTEHD6 15,745,1985 |
| oral/rat | lowest published toxic dose: 32500 mg/kg/13W- intermittent | Liver: Changes in liver weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Peptidases Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | JTEHD6 15,745,1985 |
| oral/rat | lowest published toxic dose: 27300 µg/kg/39W- intermittent | Blood: Pigmented or nucleated red blood cells Blood: Eosinophilia Blood: Changes in erythrocyte (RBC) count | GISAAA 33(10),15,1968 |
| oral/rat | lowest published toxic dose: 22750 mg/kg/13W- intermittent | Liver: Hepatitis (hepatocellular necrosis), diffuse Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | VCVGK* -,20,1994 |
| oral/rat | lowest published toxic dose: 1170 mg/kg/31W- intermittent | Gastrointestinal: Other changes Gastrointestinal: Tumors | VCVGK* -,20,1994 |
| oral/rat | lowest published toxic dose: 16250 mg/kg/13W- intermittent | Liver: Changes in liver weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain | HPV173 -,-,2002 |
| oral/rat | lowest published toxic dose: 32500 mg/kg/13W- intermittent | Liver: Changes in liver weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | HPV173 -,-,2002 |
| unreported route/mouse | lowest published toxic dose: 7000 mg/kg/2W- intermittent | Liver: Hepatitis (hepatocellular necrosis), diffuse Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | VCVGK* -,19,1994 |
Reviews
| Organization | Standard | Reference |
|---|---|---|
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-time-weighted average 10 ppm | DTLVS* TLV/BEI,2013 |
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-Confirmed animal carcinogen | DTLVS* TLV/BEI,2013 |
| TOXICOLOGY REVIEW | TOLED5 127,111,2002 | |
| TOXICOLOGY REVIEW | TOLED5 138,1,2003 | |
| TOXICOLOGY REVIEW | MUREAV 543,201,2003 | |
| TOXICOLOGY REVIEW | ENTOX* -,556,2005 | |
| TOXICOLOGY REVIEW | MUREAV 584,1,2005 | |
| TOXICOLOGY REVIEW | HUTOX* -,683,1996 | |
| TOXICOLOGY REVIEW | MUREAV 721,27,2011 | |
| TOXICOLOGY REVIEW | MUREAV 769,34,2014 | |
| TOXICOLOGY REVIEW | FCTOD7 55,596,2013 | |
| TOXICOLOGY REVIEW | MUREAV 802,1,2016 |
Standards and Regulations
| Organization | Standard | Reference |
|---|---|---|
| Mine Safety and Health Administration (MSHA) STANDARD-air | time-weighted average 75 ppm (350 mg/m3) | DTLVS* 3,49,1971 |
| Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV; | ||
| Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV | ||
| Occupational Exposure Limit-ARAB Republic of Egypt | time-weighted average 1 ppm, JAN1993 | |
| Occupational Exposure Limit-AUSTRALIA | time-weighted average 10 ppm (46 mg/m3), JUL2008 | |
| Occupational Exposure Limit-AUSTRIA | MAK-TMW 5 ppm (23 mg/m3);KZW 15 ppm (70 mg/m3), 2007 | |
| Occupational Exposure Limit-BELGIUM | time-weighted average 5 ppm (23 mg/m3), short term exposure limit 15 ppm (70 mg/m3), MAR2002 | |
| Occupational Exposure Limit-DENMARK | time-weighted average 5 ppm (23 mg/m3), MAY2011 | |
| Occupational Exposure Limit-EC | time-weighted average 47 mg/m3 (10 ppm);short term exposure limit 94 mg/m3 (20 ppm), JUN2000 | |
| Occupational Exposure Limit-FINLAND | time-weighted average 5 ppm (23 mg/m3), short term exposure limit 15 ppm (70 mg/m3), skin, NOV2011 | |
| Occupational Exposure Limit-FRANCE | VME 10 ppm (47 mg/m3), VLE 20 ppm (94 mg/m3), FEB2006 | |
| Occupational Exposure Limit-GERMANY | MAK 10 ppm (47 mg/m3), 2011 | |
| Occupational Exposure Limit-HUNGARY | time-weighted average 47 mg/m3, short term exposure limit 94 mg/m3, SEP2000 | |
| Occupational Exposure Limit-ICELAND | time-weighted average 5 ppm (23 mg/m3), short term exposure limit 15 ppm (70 mg/m3), NOV2011 | |
| Occupational Exposure Limit-JAPAN | Occupational Exposure Limit 10 ppm (46 mg/m3), MAY2012 | |
| Occupational Exposure Limit-KOREA | time-weighted average 75 ppm (350 mg/m3), 2006 | |
| Occupational Exposure Limit-MEXICO | time-weighted average 75 ppm (350 mg/m3), 2004 | |
| Occupational Exposure Limit-NEW ZEALAND | time-weighted average 10 ppm (46 mg/m3), JAN2002 | |
| Occupational Exposure Limit-NORWAY | time-weighted average 25 ppm (115 mg/m3), JAN1999 | |
| Occupational Exposure Limit-PERU | time-weighted average 10 ppm (46 mg/m3); short term exposure limit 20 ppm (92 mg/m3), JUL2005 | |
| Occupational Exposure Limit-POLAND | MAC(time-weighted average) 50 mg/m3, short term exposure limit 150 mg/m3, JAN1999 | |
| Occupational Exposure Limit-RUSSIA | time-weighted average 50 mg/m3, short term exposure limit 100 mg/m3, Skin, JUN2003 | |
| Occupational Exposure Limit-SWEDEN | time-weighted average 5 ppm (23 mg/m3);short term exposure limit 15 ppm (70 mg/m3), JUN2005 | |
| Occupational Exposure Limit-SWITZERLAND | MAK-week 10 ppm (46 mg/m3), KZG-week 20 ppm (92 mg/m3), JAN2011 | |
| Occupational Exposure Limit-THE NETHERLANDS | MAC-TGG 46 mg/m3, 2003 | |
| Occupational Exposure Limit-TURKEY | time-weighted average 75 ppm (350 mg/m3), JAN1993 | |
| Occupational Exposure Limit-UNITED KINGDOM | time-weighted average 1 ppm (4.7 mg/m3);short term exposure limit 3 ppm (14 mg/m3), skin, OCT2007 | |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) | 8H time-weighted average 75 ppm (350 mg/m3) | CFRGBR 29,1926.55,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors) | 8H time-weighted average 75 ppm (350 mg/m3) | CFRGBR 41,50-204.50,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) | 8H time-weighted average 75 ppm (350 mg/m3) | CFRGBR 29,1910.1000,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) | 8H time-weighted average 75 ppm (350 mg/m3) | CFRGBR 29,1915.1000,1993 |
NIOSH Documentation and Surveillance
Status in Federal Agencies
| Organization | Reference |
|---|---|
| ATSDR TOXICOLOGY PROFILE (NTIS** PB/91/180505/AS) | |
| EPA TSCA 8(a) PRELIMINARY ASSESSMENT INFORMATION, FINAL RULE | FEREAC 47,26992,82 |
| EPA TSCA Section 8(b) CHEMICAL INVENTORY | |
| EPA TSCA Section 8(d) unpublished health/safety studies | |
| EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001 | |
| NCI Carcinogenesis Studies (gavage);equivocal evidence:rat | |
| NCI Carcinogenesis Studies (gavage);no evidence:mouse | |
| NIOSH Analytical Method, 1994: Hydrocarbons, halogenated, 1003 | |
| NTP Carcinogenesis Studies (gavage);some evidence:rat NTPTR* NTP-TR-261,1985 | |
| On EPA IRIS database |
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health